Welcome to our dedicated page for MEDICINOVA SEC filings (Ticker: MNOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MEDICINOVA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MEDICINOVA's regulatory disclosures and financial reporting.
MediciNova furnished preliminary, unaudited results for the year ended December 31, 2025 via its Tanshin report filed with the Tokyo Stock Exchange. Revenue was $0.41M, all from a Mayo Foundation ALS research agreement, versus no revenue in 2024.
The company recorded an operating loss of $13.28M and a net loss of $12.00M, slightly higher than 2024, as research and development held around $7.2M and general and administrative expenses rose to $6.16M including Standby Equity Purchase Agreement fees. Basic and diluted net loss per share was $0.24.
Cash and cash equivalents were $30.81M as of December 31, 2025, with operating cash outflow of $9.81M. MediciNova expects 2026 operating expenses of about $16.2M (an 18% increase) and believes current cash can fund operations at least through the end of February 2027, supported by existing ATM programs and a $30.0M standby equity facility.
MediciNova Inc.'s Chief Medical Officer, Matsuda Kazuko, reported a performance-based equity award on Form 4. On January 16, 2026, the officer acquired an employee stock option to buy 350,000 shares of common stock at an exercise price of $2.10 per share, expiring on January 6, 2035. According to the disclosure, this option was originally granted on January 7, 2025 and was tied to performance criteria for the fiscal year ended December 31, 2025. Those criteria were met, resulting in full vesting of the 350,000-share option, which is now directly owned and fully exercisable.
MediciNova Inc. reported an insider equity award for its President and CEO, Yuichi Iwaki. On January 16, 2026, he acquired an employee stock option covering 450,000 shares of common stock at a $2.10 exercise price per share. These options were originally granted on January 7, 2025 and were tied to performance criteria for the fiscal year ended December 31, 2025. The filing states that the 2025 performance criteria were met, resulting in the full vesting of the option. After this transaction, Iwaki holds 450,000 derivative securities directly, with the options exercisable from January 16, 2026 and expiring on January 6, 2035.
MediciNova (MNOV) filed its Q3 2025 10‑Q, reporting modest service revenue and a wider operating loss. Revenue was $123,319, reflecting work under its Mayo agreement for ALS research. Net loss was $3,050,373, or $0.06 per share. Operating expenses were $3,504,317, with research, development and patents at $1,582,975 and general and administrative at $1,806,070, the latter elevated by Standby Equity Purchase Agreement (SEPA) fees.
Cash and cash equivalents were $32,562,612, down from $40,359,738 at year‑end, as operating cash outflows totaled $7,793,264 for the nine months. Stockholders’ equity was $43,964,756. The company recorded $521,899 of deferred revenue from Mayo and recognized $257,918 of revenue year‑to‑date. Interest income declined to $340,850 in the quarter as cash balances fell.
Liquidity and capital access: management states cash is sufficient to fund operations at least through November 2026. In July, MediciNova established a $30.0 million SEPA with Yorkville (97% of the lowest three‑day VWAP pricing mechanism; 19.99% Exchange Cap at 9,804,345 shares), and also maintains a $75.0 million ATM; no shares were sold under either program year‑to‑date. Shares outstanding were 49,046,246 as of November 10, 2025.
MediciNova, Inc. (MNOV) files an S-1 describing its clinical-stage pipeline centered on MN-166 (ibudilast) and MN-001 (tipelukast) and a financing arrangement with YA. MN-166 showed positive Phase 2b SPRINT-MS results including a 48% reduction in whole brain atrophy versus placebo (p=0.04) and a 26% reduction in risk of confirmed disability progression (HR=0.74); results were published in the New England Journal of Medicine. Multiple additional MN-166 programs reported milestones: positive Phase 2 COVID-19 ARDS topline results (statistical significance on respiratory-failure-free and hospital discharge endpoints; two placebo deaths, none on drug), IND and Orphan Drug for glioblastoma with Phase 2 enrollment completed, and ongoing/additional addiction and ophthalmic studies. MN-001 holds Fast Track designation for NASH with fibrosis and has completed/initiated several Phase 2 studies with positive subgroup and preclinical findings.
On financing, the company may sell up to $30.0 million of common stock to YA under a Purchase Agreement (registration to cover up to 25,000,000 shares). If all 25,000,000 shares were outstanding, they would represent ~51.0% of total shares and ~52.5% of non-affiliate shares (as of Aug 11, 2025). The agreement also includes an Exchange Cap limiting issuance to 9,804,345 shares (~19.99%) absent shareholder approval or price conditions. The filing lists exhibits, prior SEC filings, and signatures.
Medicinova, Inc. reports key disclosures including business risks, capital structure, segment reporting and recent lease and equity arrangements. The company lists numerous risk factors such as inability to raise capital, failure to generate product revenues, clinical trial delays or failures, reliance on its MN-166 (ibudilast) and MN-001 (tipelukast) product candidates, dependence on third parties for trials, manufacturing and commercialization, intellectual property disputes, and international and regulatory risks. Common stock authorized is 100,000,000 shares with 49,046,246 shares issued and outstanding at June 30, 2025 and December 31, 2024. The CODM evaluates performance using consolidated net loss and functional expenses. The company amended its Tokyo office lease to a 14-month term for measurement purposes using a 6.51% incremental borrowing rate. There were 970,000 performance options outstanding tied to 2025 objectives and Black-Scholes inputs are disclosed. An equity sale agreement pays 3.5% of gross proceeds to the agent. The company states strategic priorities to develop MN-166 and MN-001 and pursue non-dilutive financing and partnerships.
Form 4 filed for Medicinova, Inc. (MNOV) discloses that director Hideki Nagao received an option grant for 20,000 shares of common stock on 16 June 2025 at an exercise price of $1.26 per share. The options expire on 16 June 2035 and vest in four equal tranches on 30 Sep 2025, 31 Dec 2025, 31 Mar 2026 and 30 Jun 2026, contingent upon continued board service. No shares were sold or otherwise disposed of, and Nagao’s beneficial ownership in derivative securities increases to 20,000 options following this single transaction. The filing represents routine equity-based compensation and does not indicate any change in company fundamentals or insider sentiment beyond standard alignment incentives.
Medicinova, Inc. (MNOV) – Form 4 insider filing
On 17 June 2025, director Carolyn Beaver was granted an option to purchase 20,000 shares of Medicinova common stock. The option’s exercise price is $1.26 per share and it will expire on 16 June 2035.
The award vests in four equal installments of 5,000 shares on the following dates, contingent on continued board service:
- 30 Sep 2025
- 31 Dec 2025
- 31 Mar 2026
- 30 Jun 2026
Following this grant, Beaver reports beneficial ownership of 20,000 derivative securities and no change in non-derivative holdings was disclosed.
The transaction was coded “A” (grant) and filed as a single-reporting-person Form 4 on 20 June 2025. No 10b5-1 plan was indicated.
Investor takeaway: This appears to be a routine equity incentive award to align director interests with shareholders; the 20,000-share size is modest relative to Medicinova’s outstanding share count and therefore immaterial from a dilution standpoint.